AZN Stock Recent News

AstraZeneca's new cholesterol pill is showing promise, while the FTC urged a potential buyer of 23andMe to protect user data.

The FDA approves AZN's sBLA seeking the expanded use of Imfinzi for adult patients with muscle-invasive bladder cancer.

AstraZeneca said Monday its experimental pill lowered "bad" LDL cholesterol by 51%. The results could buoy AstraZeneca stock.

The Japanese Ministry of Health, Labour and Welfare on Thursday approved BridgeBio Pharma, Inc.‘s BBIO acoramidis, under the brand name Beyonttra, for adults with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM).

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.

AI-powered model predicts EGFR mutations from H&E-stained slides, demonstrating robust performance across diverse clinical settings and helping overcome barriers to molecular testing in NSCLC SEOUL, South Korea , March 26, 2025 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, will present a deep learning study on Epidermal Growth Factor Receptor (EGFR) mutation prediction in patients with non-small cell lung cancer (NSCLC) at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2025, held from April 25 to 30 in Chicago, Illinois. The study, which highlights the development and validation of the Lunit SCOPE Genotype Predictor, an AI-powered deep learning model capable of predicting EGFR mutations directly from hematoxylin and eosin (H&E)-stained tissue samples in NSCLC patients, will be presented in collaboration with AstraZeneca (LSE/STO/Nasdaq: AZN).

AstraZeneca PLC (LSE:AZN) and GSK PLC (LSE:GSK, NYSE:GSK) remain among Berenberg's top picks in the pharmaceuticals sector, with the broker reaffirming its 'buy' rating on both stocks. The former carries a target price of £140, while the valuation for stock in the latter is £16.

The tech-heavy Nasdaq Composite index recently entered correction territory. Though it was able to climb out of it, equities broadly remain down for the year.

British pharmaceutical giant AstraZeneca announced on Friday that it will invest $2.5 billion in a research and development center in the Chinese capital.

Pascal Soriot, CEO of British pharmaceutical giant AstraZeneca, discusses the company's $2.5 billion investment in a new China research and development center.